Keith R. Leonard, Jr. is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board since August 2005. From 1991 to 2004, Mr. Leonard held various positions at Amgen Inc., a biotechnology company, and its affiliates, or Amgen. From 2001 to 2004, Mr. Leonard served as Senior Vice President and General Manager of Amgen Europe where he was responsible for all commercial operations in 28 European countries. Prior to that role, Mr. Leonard established Amgen’s presence in rheumatology with the creation of the Rheumatology Business Unit, served as Head of Information Management, and served in leadership roles in sales and marketing, engineering, operations, and finance. Mr. Leonard previously served on the boards of Affymax, Inc. and ARYx Therapeutics, Inc. He was formerly an active duty officer in the U.S. Navy. Mr. Leonard received a B.S. in Engineering from the University of California, Los Angeles, a B.A. in History from the University of Maryland, a M.S. in Engineering from the University of California, Berkeley, and a M.B.A. from the Anderson School of Management at the University of California, Los Angeles.
Frederick Beddingfield, III, M.D., Ph.D. has served as our Chief Medical Officer since March 23, 2013. Prior to his appointment at Kythera, he held the role of Vice President and Global Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. from August 2005 until March 2013. Dr. Beddingfield, a board certified dermatologist with fellowship training in aesthetic, procedural dermatology and Mohs surgery, lead the global clinical development programs for premiere products in the dermatology and aesthetics industry, including Allergan’s BOTOX® Cosmetic, JUVEDERM® and LATISSE®, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield served in several roles, including Chief Medical Officer from December 2008 to August 2010 of Allergan Medical, and Global Team Leader of several brands and was a key champion and driver of Allergan’s large research and development pipeline in dermatology and aesthetics. Earlier in his career, he held a full-time faculty position at the David Geffen School of Medicine at UCLA, Division of Dermatology, where he continues to maintain a practice and academic appointment as Assistant Clinical Professor of Medicine. Dr. Beddingfield received an M.D. degree with honors from the University of North Carolina, a Ph.D. in Policy Analysis from RAND Graduate School of Policy Studies and a B.A. in Psychology from North Carolina State University.
Elisabeth A. Sandoval has served as our Chief Commercial Officer since March 2012. From December 2010 to March 2012, Ms. Sandoval served as Vice President of Global Marketing and Strategy at Bausch + Lomb Surgical, a medical device company, where she was responsible for creating and leading the global marketing team. Prior to that experience, she spent more than 20 years at Allergan from March 1988 to November 2010 where she held roles of increasing responsibility that spanned from research and development to sales and marketing. Her tenure at Allergan included the role of Vice President of Global Strategic Marketing for Allergan, where she was involved in the launch of JUVEDERM®, and headed the global marketing team for BOTOX® Cosmetic, LATISSE®, Natrelle® breast implants and LAP-B.A.ND®. Ms. Sandoval received a B.S. in Biology from the University of California, Irvine and a M.B.A. from Pepperdine University.
John W. Smither has served as our Chief Financial Officer since November 2007. From 1999 to 2007, Mr. Smither held various positions at Amgen. From 2001 to 2004, Mr. Smither served as Vice President of Finance and Administration of Amgen’s European Division, where he was responsible for financial operations in 28 European countries. Prior to that role, Mr. Smither served as Head of Internal Audit and Executive Director of Corporate Accounting at Amgen. Prior to joining Amgen, Mr. Smither served as Audit Partner at Ernst & Young LLP, a public accounting firm, and as the Chief Financial Officer of several early stage companies. Mr. Smither received a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.
Jeffrey D. Webster has served as our Senior Vice President, Operations since March 2007. From 1996 to 2005, Mr. Webster held various positions at Amgen where he ultimately served as Vice President, Operations Planning, responsible for product development, project management, training and development, and strategy functions within the operations function. Prior to that role, Mr. Webster served as the product development team leader for NEUPOGEN®/ Neulasta® and held positions in process development, engineering, investor relations, marketing, product development, portfolio management, corporate development and strategy, and operations. Mr. Webster received a B.S. in Chemical Engineering from the University of California, Berkeley and a M.B.A. from San Jose State University.
Keith L. Klein, J.D. has served as our General Counsel since October 2006. From 1991 to 2006, Mr. Klein held various positions of increasing responsibility in the legal department of Amgen where he ultimately served as Senior Associate General Counsel, responsible for legal activities relating to the areas of sales and marketing, federal government affairs, corporate relationships, manufacturing, product supply, product development and real estate. Mr. Klein received a B.A. in Economics from University of California, Los Angeles and a J.D. from the University of California, Davis.
Deepak Chadha has served as our Vice President, Regulatory Affairs since August 2007. From August 2004 to July 2007, Mr. Chadha served as Vice-President, Global Regulatory Affairs at Allergan, Inc. where he assisted in building the Global Regulatory Affairs Department and was responsible for developing and implementing global regulatory strategies. Prior to that experience, from November 1999 to August 2004, Mr. Chadha held positions of increasing responsibility at Biomeasure Inc. and Stryker Biotech. Mr. Chadha received a B.S. in Pharmaceutical Sciences from Berhampur University in Orissa, India, a M.S. in Pharmaceutics from Hamdard University in New Delhi, India, and a M.B.A. in International Business from California State University, Dominguez Hills.
Jere Fellmann, Ph.D., has served as our Vice President, Clinical Affairs since June 2012. Dr. Fellmann was the co-founder of Ocellus Inc., a multidisciplinary consulting company, and has served as its Director of since its founding in 1996 to the present day. Dr. Fellmann was Vice President, Clinical Operations and Project Management from October 2004 to September 2007 at Acologix, Inc, a biopharmaceutical company. Dr. Fellmann has also held leadership positions at various other life sciences companies, including Eunoe, Inc., Symyx Technologies, Elan Pharmaceutical, Inc. and Neurex Corporation. Dr. Fellmann has authored or co-authored numerous publications and patents. Dr. Fellmann received a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Inorganic/Organometallic Chemistry from the Massachusetts Institute of Technology.
Subhas Gupta joined Kythera in May 2012 to establish our Medical Affairs function, bringing nearly 15 years experience in academic plastic surgery. He has a broad clinical practice based at Loma Linda University using his expertise in aesthetic surgery focusing on facial rejuvenation and breast and body contouring as well as technology-enhanced surgery such as endoscopic, laser and ultrasound methods.
After graduating from McGill University School of Medicine in Montreal, Canada, Dr. Gupta spent nearly a decade in post-graduate training completing residency training and fellowships in General Surgery, Plastic and Reconstructive Surgery, Hand and Microsurgery, Aesthetic and Laser Surgery, and Patient Safety. He has also undertaken additional training in cosmetic skin care, anti-aging medicine, nutrition and exercise physiology. He is a member of the American Society of Plastic Surgeons, the American Association of Plastic Surgeons, the Plastic Surgery Research Council, the American College of Surgeons and several other national groups. Subhas has published over 70 scientific articles and textbook chapters and serves on several scientific review and editorial boards. He has been well recognized for his contributions to research in cosmetic surgery, minimally invasive techniques, laser surgery, scar control, informatics, outcomes assessment, and wound healing with funded fellowships, research grants, and paper/presentation awards from numerous specialty and national societies.
Nancy A. Jorgesen has served as our Vice President, Product, Systems and Alliance Management since January 2012. From January 2007 to December 2011, Ms. Jorgesen served as our Product Team Leader for ATX-101. She is also responsible for the alliance management of our partnership with Bayer. Ms. Jorgesen was previously at Amgen for over 10 years, where she held roles of increasing responsibility in Rheumatology product development, corporate process improvement and change management and molecular biology and protein chemistry research. Prior to that experience, Ms. Jorgesen served as the Product Development Team Leader for the Animal Health unit of Dow AgroSciences, a plant sciences company, focusing on the development of edible vaccines. Ms. Jorgesen received a B.S. in Microbiology and a M.A. in Biochemistry and Molecular Biology from the University of California, Santa Barbara and a M.B.A. from the University of Illinois at Urbana-Champaign.
Serge Lichtsteiner, Ph.D. has served as our Vice President, Research since September 2009. From May 2009 to September 2009, Dr. Lichtsteiner served as a consultant to us, and from September 2008 to April 2009, he was an independent consultant. From November 2002 to August 2008, Dr. Lichtsteiner served successively as the Director of Molecular Biology, Director of Molecular and Cell Biology, and Director of Lead Discovery and Molecular Biology for Cytokinetics, Inc., a biotechnology company, where he was responsible for multiple functional teams in charge of generating the company's product pipeline and supporting all early stages of drug discovery efforts. Prior to that experience, from November 1991 to November 2002, Dr. Lichtsteiner served as Associate Director and Head of Molecular Biology at Pfizer Global Research and Development, an affiliate of Pfizer Inc., where he was responsible for a team focused on providing engineered, recombinant proteins to enable target validation and lead optimization. Dr. Lichtsteiner holds numerous pending and issued patents in oncology, drug discovery technology, and protein chemistry. Dr. Lichtsteiner received a B.S. in Biology, a M.S. in Molecular Biology, and a Ph.D. in Molecular Biology, all from the University of Geneva in Switzerland.
Susan R. Lundeen has served as our Vice President, Human Resources since October 2006. From September 2005 to June 2007, Ms. Lundeen was Vice President of Human Resources and Administration at Activus Healthcare Solutions, Inc., a healthcare company, where she was responsible for designing people systems and decision-making processes. Prior to that experience, from February 1993 to September 2005, Ms. Lundeen held various positions at Amgen and ultimately served as Senior Director of Human Resources responsible for Strategic Sourcing and Staffing. Ms. Lundeen received a B.A. in Psychology and Business Administration from California Lutheran University and currently sits on the Board of Regents for California Lutheran University.
Dr. Paul F. Lizzul, has served as our Medical Director since August 2012. Dr. Lizzul is a diplomat of the American Board of Dermatology and a faculty member of the American Academy of Dermatology (AAD). He holds leadership positions within the national dermatology community and also held the distinction of serving on the Food and Drug Administration (FDA) Dermatology and Ophthalmic Drugs Advisory Committee.
Dr. Lizzul has a broad depth of knowledge and experience in both clinical and bench research and medical practice. Prior to joining KYTHERA, Dr. Lizzul served as an Assistant Professor of Dermatology and Associate Director of Clinical Research at Tufts Medical Center. He is a Summa Cum Laude graduate of Rensselaer Polytechnic Institute, and received his M.D., Ph.D. degrees in Molecular Genetics and Microbiology, and M.P.H. in Epidemiology/Outcomes from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School.
Dr. Lizzul also earned an M.B.A. from the Rutgers Business School and is the recipient of numerous awards and accolades, including appointment to the American Academy of Dermatology (AAD) academic leadership program, the American Society of Dermatologic Surgery (ASDS) mentorship award, the Dr. Alan Scott Research Award from the American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS), a Gallo award for outstanding Cancer Research, and recipient of NIH training grants.
 Tazorac®, BOTOX® Cosmetic, Juvederm®, Bioenterics® LAP-B.A.ND® and Inamed® Silicone gel-filled Breast Implants are registered trademarks of Allergan, Inc. Hylaform® and Captique® are registered trademarks of Genzyme Corporation.
 NEUPOGEN®/NEULASTA®, Aranesp®, Kineret® Sensipar® and Enbrel® are registered trademarks of Amgen Inc.